Precision microbiota therapy for IBD: premise and promise

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis (UC) and Crohn's Disease (CD), is a chronic intestinal inflammatory condition without a cure.
• Genetic, environmental, and immunological factors contribute to IBD pathogenesis.
• Recent advances reveal significant gut microbiota alterations in IBD patients.

Purpose of the Study:

• To review preclinical and clinical evidence supporting microbiome-based therapeutics for IBD.
• To propose a framework for developing precision microbiome therapeutics for IBD.
• To enhance the efficacy and safety of IBD therapies through targeted microbial interventions.

Main Methods:

• Review of existing scientific literature on IBD and microbiome research.
• Analysis of preclinical studies investigating microbial roles in IBD.
• Evaluation of clinical trials on microbiome-targeted therapies for IBD.

Main Results:

• Gut microbiota signatures are implicated in IBD pathogenesis.
• Fecal microbiota transplantation (FMT) success in other conditions supports microbiome therapy potential for IBD.
• Precision in donor/recipient selection, diet, and strain-specific interactions is crucial for therapeutic success.

Conclusions:

• Microbiome-based therapies represent a promising avenue for IBD treatment.
• Developing precision microbiome therapeutics is essential for optimizing patient outcomes.
• Further research is needed to refine strategies for microbiome modulation in IBD.